| 000 | 01791 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516102352.0 | ||
| 264 | 0 | _c20130102 | |
| 008 | 201301s 0 0 eng d | ||
| 022 | _a1096-1186 | ||
| 024 | 7 |
_a10.1016/j.phrs.2012.07.001 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBishnoi, Harish Kumar | |
| 245 | 0 | 0 |
_aThe combined strategy with PPARα agonism and AT₁ receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat. _h[electronic resource] |
| 260 |
_bPharmacological research _cOct 2012 |
||
| 300 |
_a349-56 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAngiotensin II Type 1 Receptor Blockers _xpharmacology |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBenzimidazoles _xpharmacology |
| 650 | 0 | 4 |
_aBenzoates _xpharmacology |
| 650 | 0 | 4 |
_aBlood Glucose _xmetabolism |
| 650 | 0 | 4 |
_aCreatine _xblood |
| 650 | 0 | 4 |
_aDiabetes Mellitus _xchemically induced |
| 650 | 0 | 4 |
_aDiabetic Nephropathies _xblood |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFenofibrate _xpharmacology |
| 650 | 0 | 4 |
_aHypolipidemic Agents _xpharmacology |
| 650 | 0 | 4 |
_aKidney _xdrug effects |
| 650 | 0 | 4 |
_aLipids _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aNitrogen _xblood |
| 650 | 0 | 4 |
_aOxidative Stress _xdrug effects |
| 650 | 0 | 4 |
_aPPAR alpha _xagonists |
| 650 | 0 | 4 |
_aProteinuria _xprevention & control |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Wistar |
| 650 | 0 | 4 | _aStreptozocin |
| 650 | 0 | 4 | _aTelmisartan |
| 700 | 1 | _aMahadevan, Nanjaian | |
| 700 | 1 | _aBalakumar, Pitchai | |
| 773 | 0 |
_tPharmacological research _gvol. 66 _gno. 4 _gp. 349-56 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.phrs.2012.07.001 _zAvailable from publisher's website |
| 999 |
_c21945016 _d21945016 |
||